CureVac said his vaccine against
COVID was 48% effective in the final analysis of its
crucial mass trial, only marginally better than the 47% reported after an initial reading two weeks ago.
The
German biotech firm said that efficacy, as measured by preventing symptomatic disease, was slightly better (53%) when excluding trial participants older than 60, an age group that is by far the most severely affected.
CureVac said on June 16 that its vaccine against
COVID, known as
CVnCoV, proved to be only 47% effective on an initial test reading and that the new variants had provided an adverse factor, undermining investor confidence in its ability to deal with rival injections.
Covid Live Updates: Layers of Red Tape Burden U S Vaccine Donations
nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.
Corona aktuell: RKI meldet erneut gesunkene Inzidenz
sueddeutsche.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sueddeutsche.de Daily Mail and Mail on Sunday newspapers.
Covid vaccine from Germany s CureVac just 48% effective Thu 01st July 2021 | 08:50 AM
Frankfurt, (UrduPoint / Pakistan Point News - 1st Jul, 2021 ) :Germany s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed the unprecedented context of 15 strains circulating among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany s BioNTech in partnership with US giant Pfizer and by US firm Moderna based on the same novel messenger RNA technology were approved earlier on in the pandemic after showing around 95 percent efficacy.
Covid vaccine from Germany´s CureVac just 48% effective
By
Thursday Jul 01, 2021
FRANKFURT: Germany´s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed the unprecedented context of 15 strains circulating among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany´s BioNTech in partnership with US giant Pfizer and by US firm Moderna based on the same novel messenger RNA technology were approved earlier on in the pandemic after showing around 95 percent efficacy.